Edition:
United Kingdom

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

2.25USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
236,536
52-wk High
$24.00
52-wk Low
$1.65

Select another date:

Mon, Dec 4 2017

BRIEF-Versartis Inc Says Board Appointed Jay Shepard, CEO, To Position Of Principal Financial Officer

* VERSARTIS INC SAYS ‍ON NOV 28, 2017, BOARD APPOINTED JAY SHEPARD, CEO, TO POSITION OF PRINCIPAL FINANCIAL OFFICER, EFFECTIVE DEC 1, 2017 - SEC FILING​ Source text (http://bit.ly/2A3BTve) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Versartis hires Cowen to assist in evaluating potential strategic transactions

* Versartis hires Cowen to assist in evaluating potential strategic transactions

BRIEF-Versartis reports Q3 loss $1.40/shr

* Versartis reports third quarter 2017 financial results and provides corporate update

Versartis growth hormone drug fails key study, shares sink

Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

Versartis growth hormone drug fails key study, shares sink

Sept 21 Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

BRIEF-Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

* Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

BRIEF-Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​

* Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​ Source text: (http://bit.ly/2vdEZZz) Further company coverage:

BRIEF-Versartis reports Q2 loss per share $1.04

* Q2 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Select another date: